1. Home
  2. EQS vs LNAI Comparison

EQS vs LNAI Comparison

Compare EQS & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Equus Total Return Inc.

EQS

Equus Total Return Inc.

HOLD

Current Price

$1.40

Market Cap

18.9M

Sector

Finance

ML Signal

HOLD

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

N/A

Current Price

$0.80

Market Cap

20.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EQS
LNAI
Founded
1991
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.9M
20.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EQS
LNAI
Price
$1.40
$0.80
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
9.3K
182.3K
Earning Date
01-01-0001
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,377,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.11
N/A
52 Week Low
$0.74
$0.79
52 Week High
$2.49
$14.00

Technical Indicators

Market Signals
Indicator
EQS
LNAI
Relative Strength Index (RSI) 36.93 36.76
Support Level $1.30 $0.79
Resistance Level $1.42 $0.97
Average True Range (ATR) 0.06 0.09
MACD 0.01 -0.00
Stochastic Oscillator 41.33 18.16

Price Performance

Historical Comparison
EQS
LNAI

About EQS Equus Total Return Inc.

Equus Total Return Inc is a United States-based closed-end management investment company. It invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: